title: Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study.
abstract: OBJECTIVE
  To compare patients' health status function after treatment with thermal balloon endometrial ablation (TBEA) and levonorgestrel intrauterine system (LNG-IUS) for idiopathic menorrhagia.
  
  
  METHODS
  Forty-four patients were recruited into a randomized trial comparing their health status after treatment with TBEA or LNG-IUS for idiopathic menorrhagia.
  
  
  RESULTS
  At 1 year follow-up, the mean haemoglobin was significantly higher in women treated with TBEA (12.6 g/dl vs. 10.3 g/dl, p = 0.018). Iron deficiency occurred in 13.3% from the TBEA arm and in 50% from the LNG-IUS arm (p = 0.026). The women's mean Short Form 36 Questionnaire general health perception scores (54.9 vs. 40.5, p = 0.024) and mental health scores (49.5 vs. 38.3, p = 0.021) in TBEA arm were significantly higher than in the LNG-IUS arm. The mental health domain score was also significantly lower in the LNG-IUS arm (46.1 vs. 38.3, p = 0.041).
  
  
  CONCLUSIONS
  TBEA appears to offer better health status function at 1 year follow-up and to be more acceptable to our Chinese population in the treatment of idiopathic menorrhagia following failed medical treatment.
authors.affiliation: Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, SAR, China. tamwh@cuhk.edu.hk
authors.forename: Wing Hung
authors.initials: WH
authors.lastname: Tam
authors.forename: Pong Mo
authors.initials: PM
authors.lastname: Yuen
authors.forename: Doris Pui
authors.initials: DP
authors.lastname: Shan Ng
authors.forename: Pui Ling
authors.initials: PL
authors.lastname: Leung
authors.forename: Ingrid Hung
authors.initials: IH
authors.lastname: Lok
authors.forename: Michael Scott
authors.initials: MS
authors.lastname: Rogers
mesh_terms: D000328:Adult; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D002404:Catheterization / Q000009:adverse effects / Q000379:methods*; D003271:Contraceptive Agents, Female / Q000009:adverse effects / Q000627:therapeutic use*; D004717:Endometrium; D005260:Female; D005500:Follow-Up Studies; D006304:Health Status; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007436:Intrauterine Devices, Medicated; D000090463:Iron Deficiencies; D016912:Levonorgestrel / Q000009:adverse effects / Q000627:therapeutic use*; D008595:Menorrhagia / Q000150:complications / Q000628:therapy*; D008603:Mental Health; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D003271:Contraceptive Agents, Female; D006454:Hemoglobins; D016912:Levonorgestrel